Compensation award — excluded from discretionary-purchase analysis.
Loading…
Mark J Enyedy is Director at BioMarin Pharmaceutical. OQRO lists 2 transactions filed with the SEC under this name, the latest on Jun 4, 2026, each linked to the official Form 4.
Director
Disclosures on record
2
Companies involved
2
Compensation award — excluded from discretionary-purchase analysis.
Compensation award — excluded from discretionary-purchase analysis.